BTL Exomind Subtitles

The BTL webinar, EXOMIND: Revolutionizing Mental Wellness with Advanced Neurostimulation, occurred on September 24, 2025, hosted on BTL's professional education platform. Moderated by Prof. Patrick Treacy from Ireland, it drew over 500 registrants from aesthetics, psychiatry, and plastic surgery. The 90-minute session focused on EXOMIND’s 2025 FDA-cleared rollout. EXOMIND, launched by BTL in January 2025, is a non-invasive transcranial magnetic stimulation device using patented ExoTMS technology, delivering electromagnetic pulses to brain regions like the dorsolateral prefrontal cortex to enhance neuroplasticity for emotional regulation, focus, and self-control. Key Points: • FDA Clearance and Protocol: Cleared for major depressive disorder in treatment-resistant adults; EU/CE-marked for anxiety, OCD, and binge eating. Sessions last 20-30 minutes, 4-6 over 1-3 weeks, with no downtime. • Advantages Over Traditional TMS: Gentler pulses ensure 95% of trial patients reported comfort, with AI-guided targeting and aesthetic integration for pre/post-procedure anxiety relief. • Evidence: 2024-2025 trials with over 200 participants show 80-90% mood improvement with minimal side effects. Prof. Patrick Treacy’s Historical Deep Dive Prof. Treacy framed EXOMIND as the result of 100 years of magnetic mastery: • 19th Century: Faraday’s 1831 electromagnetic induction led to d’Arsonval’s 1890s electromagnetic baths for hysteria, early TMS precursors. • 1930s-1950s: Electroconvulsive therapy by Cerletti and Bini in 1938 achieved 90% efficacy for depression but caused amnesia, spurring gentler methods. • 1980s: Anthony Barker’s 1985 TMS prototype enabled painless stimulation. Mark George’s 1995 study showed 50% depression relief via DLPFC activation. • 2000s-2020s: Deep TMS, approved for OCD in 2013, and theta-burst protocols cut session counts. BTL’s 2024 patents reduced sessions to 6: From Frankenstein’s lab to a spa chair. Treacy contrasted Mesmer’s debunked magnetism with modern ethical trials. Treacy said, EXOMIND democratizes brain health, bridging med spas and mental health clinics. His talk sparked 20+ Q&A questions on GLP-1 parallels, concluding: EXOMIND is the ethical endpoint of 30+ years of safe TMS data. Prof. Reha Yavuzer’s Results: Turkey, Plastic Surgeon Prof. Yavuzer from Ankara University shared 2025 trial data with 52 pre-op body contouring patients: • Cohort: 65% female, aged 35-55, with GAD/depression from body image concerns. • Protocol: 5 sessions, pre-op Days -3 to +2, DLPFC-targeted. • Results: 88% anxiety reduction, GAD-7 score dropping from 15 to 4; 85% better surgical satisfaction. A 40-year-old rhinoplasty patient with BDD cut mirror-checking by 70%, avoiding revisions. At 6 months, 82% sustained gains, with 15% fewer complications. • Quote: EXOMIND turns ‘what if I hate it?’ into ‘I’m ready.’ It cut no-shows by 25%. He demoed a session setup, noting Turkey’s med spa adoption. Prof. Ali Ghanem’s Results with Binge Eating: UK, Plastic Surgeon Prof. Ghanem from UCL Hospitals presented a 2025 BTL study with 35 post-bariatric patients: • Profile: 70% post-gastric bypass, 4+ binges/week. • Approach: 6 sessions over 2 weeks, targeting self-control. • Outcomes: 84% binge reduction, from 5.2 to 1.8 episodes/week; 91% self-control boost. A 39-year-old male post-panniculectomy halved emotional eating: EXOMIND gave him a neural pause button. • Impact: 79% mood uplift; 20% fewer revisions. Ghanem: A game-changer for behavioural plastics. Dr. Michelle Dees on Anxiety and Depression: US Psychiatrist Dr. Dees from Chicago’s Luxury Psychiatry Clinic shared 2025 trial results with 40 participants: • Anxiety: A 42-year-old executive with GAD/panic saw 80% relief, GAD-7 score dropping from 19 to 4 post-4 sessions: Like uninstalling the anxiety app. 89% of anxiety patients gained resilience; 75% resumed social activities. • Depression: A 50-year-old with MDD/PTSD had 92% PHQ-9 improvement in Week 1. A 36-year-old with perinatal depression/anxiety said, The numbness thawed—I bonded with my baby. 86% well-being surge via WEMWBS; 90% preferred EXOMIND over pills for zero fog. • Takeaway: Dees noted tailored pulses: Anxiety and depression tango—EXOMIND harmonizes them. 87% saw relational benefits. ADHD overlap showed 85% focus gains. Wrap-Up The webinar ended with Q&A on coding and EMFACE combos, with BTL offering trials. Feedback showed 96% satisfaction. Access the recording via BTL’s portal at providers@btl.net. Treacy teased a longevity follow-up. Contact BTL for slides or studies